Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Feature: Brief Communication
  • Published:

Steffimycin E, a new anti-mycobacterial agent against Mycobacterium avium complex, produced by Streptomyces sp. OPMA02852

The Journal of Antibiotics volume 73, pages 581–584 (2020)Cite this article

Subjects

Abstract

The marine actinomycete strain OPMA02852, identified as the genus Streptomyces, was found to produce anti-mycobacterial compounds against Mycobacterium avium complex (MAC). One new compound, designated as steffimycin E (1), was isolated together with three known steffimycins (steffimycin (2), 10-dihydrosteffimycin (3), and 8-demethoxysteffimycin (4)) from the culture broth of this producing microorganism by solvent extraction, ODS column chromatography, and preparative HPLC. Compound 1 has a tetracyclic quinone structure with a sugar moiety. Compound 1 exhibited anti-mycobacterial activity against M. intracellulare, M. bovis BCG, and M. smegmatis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22:1116–7.

    Article  Google Scholar 

  2. Adjemian J, Olivier NC, Seitz EA, Holland MS, Prevots RD. Prevalence of nontuberculous mycobacterial lung disease in U.S. medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.

    Article  Google Scholar 

  3. Bergy EM, Reusser FA. new antibacterial agent (U20,661) isolated from a streptomycete strain. Experientia. 1967;23:254–5.

    Article  CAS  Google Scholar 

  4. Wiley PF, Elrod DW, Slavicek JM, Marshall VP. Microbial conversion of steffimycin and steffimycin B to 10-dihydrosteffimycin and 10-dihydrosteffimycin B. J Antibiot. 1980;33:819–23.

    Article  CAS  Google Scholar 

  5. Kunnari T, Tuikkanen J, Hautala A, Hakala J, Ylihonko K, Mäntsälä P. Isolation and characterization of 8-demethoxy steffimycins and generation of 2,8-demethoxy steffimycins in Streptomyces steffisburgensis by the nogalamycin biosynthesis genes. J Antibiot. 1997;50:496–501.

    Article  CAS  Google Scholar 

  6. Gullón S, Olano C, Abdelfattah MS, Braña AF, Rohr J, Méndez C, et al. Isolation, characterization, and heterologous expression of the biosynthesis gene cluster for the antitumor anthracycline steffimycin. Appl Environ Microbiol. 2006;72:4172–83.

    Article  Google Scholar 

  7. Kelly CR, Schletter I, Koert MJ, MacKellar AF, Wiley FW. Structures of steffimycin and steffimycin B1. J Org Chem. 1977;22:3591–6.

    Article  Google Scholar 

  8. Koyama N, Kojima S, Nonaka K, Masuma R, Matsumoto M, Omura S, et al. Calpinactam, a new anti-mycobacterial agent, produced by Mortierella alpina FKI-4905. J Antibiot. 2010;63:183–6.

    Article  CAS  Google Scholar 

  9. Kaneko M, Matsuda D, Ohtawa M, Fukuda T, Nagamitsu T, Yamori T, et al. Potentiation of bleomycin in jurkat cells by fungal pycnidione. Biol Pharm Bull. 2012;35:18–28.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We express our thanks to Ms Noriko Sato and Dr Kenichiro Nagai, School of Pharmacy, Kitasato University for the measurements of NMR spectra and MS data, respectively. This work was supported by JSPS KAKENHI grant numbers 26253009 (HT) and 15K07867 (NK) from the Ministry of Education, Culture, Sport, Science, and Technology, Japan.

Author information

Authors and Affiliations

  1. Department of Microbial Chemistry, Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan

    Nobuhiro Koyama, Satoru Shigeno & Hiroshi Tomoda

  2. Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan

    Nobuhiro Koyama, Satoru Shigeno & Hiroshi Tomoda

  3. OP BIO FACTORY Co., Ltd., 5-8 Suzaki, Uruma-shi, Okinawa, 904-2234, Japan

    Akihiko Kanamoto

Authors
  1. Nobuhiro Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Shigeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akihiko Kanamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Tomoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Nobuhiro Koyama or Hiroshi Tomoda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Dedicated to Professor William Fenical in recognition of his contributions to marine-derived secondary metabolites.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koyama, N., Shigeno, S., Kanamoto, A. et al. Steffimycin E, a new anti-mycobacterial agent against Mycobacterium avium complex, produced by Streptomyces sp. OPMA02852. J Antibiot 73, 581–584 (2020). https://doi.org/10.1038/s41429-020-0290-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-020-0290-9

This article is cited by

Search

Advanced search

Quick links